{"id":"W2399436709","doi":"10.1016/j.jval.2016.03.1315","title":"CHARACTERISTICS OF PATIENTS INITIATING TREATMENT WITH DULAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Dulaglutide; Exenatide; Medicine; Liraglutide; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Diabetes mellitus; Endocrinology; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002938431,0.0002170412,0.0007002098,0.0007042013,0.000503474,0.0007241571,0.0002436112,0.0006736565,0.005844602],"category_scores_gemma":[0.002053425,0.0001832663,0.0009646091,0.001217224,0.0002560072,0.0006453324,0.0003001796,0.001021788,0.0005262372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004366026,"about_ca_system_score_gemma":0.0006666277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002410887,"about_ca_topic_score_gemma":0.002323328,"domain_scores_codex":[0.9995562,0.00004370837,0.00007358338,0.00009704378,0.00006497936,0.0001643582],"domain_scores_gemma":[0.9983096,0.0005348151,0.0005769334,0.00005341752,0.00009381863,0.0004313698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003470063,0.0005235913,0.9875893,0.00005007703,0.000175591,0.0007173694,0.0001261602,0.000188117,0.001130469,0.0001112073,0.0006099364,0.00530805],"study_design_scores_gemma":[0.0001317134,0.001323764,0.994302,0.00003334874,0.00009400314,0.00160485,0.0005336996,0.0003094322,0.0001368787,0.0001075575,0.001401919,0.00002067318],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931387,0.0009343774,0.0001074536,0.0001552747,0.00002708366,0.00003388219,0.001814593,0.000008041857,0.00378052],"genre_scores_gemma":[0.996029,0.0005022982,0.00008199425,0.0003186256,0.00006153168,0.00004964758,0.001889885,0.000006579046,0.00106057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005844602,"threshold_uncertainty_score":0.01955211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03022752582593738,"score_gpt":0.2733063494825924,"score_spread":0.243078823656655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}